Guillain-Barre, the rare autoimmune disorder, causes the immune system to attack the nerves.
About 100 preliminary cases of Guillain-Barre have been detected in Americans after they received one of the more than 12.8 million Johnson & Johnson doses distributed, according to the publication. These cases occurred about two weeks following vaccination and largely impacted men over the age of 50.
One case that was reported through the federal monitoring system was a 57-year-old man from Delaware who had suffered a heart attack and stroke within the last four years. He died in early April after he was vaccinated and developed the rare autoimmune disorder.
Regulators said that cases were extremely rare, but it appeared to be three to five times higher among people who received a Johnson & Johnson vaccine compared to the general population.
Typically the US records about 60 to 120 cases of Guillain-Barre per week, with about 3,000 to 6,000 people developing the rare disorder per year, according to the Centers for Disease Control and Prevention.
The Biden administration was expected to issue a warning about the Johnson & Johnson vaccine as early as Tuesday, according to the report.
“The safety and well-being of the people who use our products is our number one priority,” Johnson & Johnson said in a statement to The Independent.
“We have been in discussions with the US Food and Drug Administration and other regulators about rare cases of the neurological disorder, Guillain-Barré syndrome, that have been reported following vaccination with the Janssen Covid-19 vaccine. The chance of having this occur is very low, and the rate of reported cases exceeds the background rate by a small degree.”
The company went on to state that it “strongly support raising awareness of the signs and symptoms of rare events to ensure they can be quickly identified and effectively treated.”
The FDA confirmed to The Independent that it would issue a warning.
“Although the available evidence suggests an association between the Janssen vaccine and increased risk of GBS, it is insufficient to establish a causal relationship. No similar signal has been identified with the Moderna and Pfizer-BioNTech Covid-19 vaccines,” a spokesperson said.
“FDA continues to work with its partner in vaccine safety surveillance, the CDC, to monitor reports of GBS following vaccination with the Janssen Covid-19 Vaccine. Importantly, the FDA has evaluated the available information for the Janssen Covid-19 Vaccine and continues to find the known and potential benefits clearly outweigh the known and potential risks.”
Guillain-Barre can cause muscle weakness and paralysis in individuals, according to the CDC. Symptoms can last for several weeks to a year, but typically go away and people make a full recovery. In some cases, though, the person experiences permanent nerve damage.
How the rare autoimmune disorder develops remains unknown, but experts have found it can come following viral infections, such as the flu or the Zika virus.
“About two-thirds of people with GBS had diarrhoea or a respiratory illness several weeks before developing symptoms,” according to the CDC. “Very rarely, people have developed GBS in the days or weeks after receiving certain vaccines.”
Despite issuing the warning, officials were expected to reiterate the safety of the Covid-19 vaccine and how its benefits outweigh the potential risks, The Washington Post reports.
But this comes as a blow amid declining vaccination rates across the country.
Health officials have expressed concerns that news of a new FDA warning could further push people away from ever getting a Covid-19 vaccine. This as highly transmissible variants of Covid-19 continue to spread – increasing cases, hospitalisations, and deaths, specifically among the unvaccinated.
To date, 48 per cent of Americans were fully vaccinated against Covid-19 and 55.5 per cent of the public has received at least one dose, according to data released by the CDC. Almost one-third of the country’s adults remain unvaccinated.
Register for free to continue reading
Registration is a free and easy way to support our truly independent journalism
By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists
Already have an account? sign in
Join our new commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies